FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression
Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin- dependent kinase 4/6, a type of enzyme.
For patients with extensive-stage small cell lung cancer, protecting bone marrow function may help make their chemotherapy safer and allow them to complete their course of treatment on time and according to plan. Today s approval of Cosela will give patients a treatment option that can reduce the occurrence of a common, harmful side effect of chemotherapy.
Researchers in the United States have identified specific immune correlates that might be key to ensuring that vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protects against not only disease, but also viral transmission and emerging variants.
Experimental drug can speed up Covid-19 recovery: Study
Experimental drug can speed up Covid-19 recovery: Study
Scientists have found that an experimental antiviral drug can significantly speed up recovery in Covid-19 patients who do not need hospitalisation, an advance that may lead to better interventions to treat those infected with the novel coronavirus.
advertisement
UPDATED: February 8, 2021 18:51 IST
The study noted that patients who received a single injection of the new antiviral drug were over four times more likely to have cleared the infection within 7 days (Picture Credits: Reuters)
Scientists have found that an experimental antiviral drug can significantly speed up recovery in Covid-19 patients who do not need hospitalisation, an advance that may lead to better interventions to treat those infected with the novel coronavirus.
Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).
First-of-its-kind cardiovascular drug gets FDA approval based on study from Canadian VIGOUR Centre
The U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure. The drug a first-of-its-kind, once-daily oral treatment for patients with worsening chronic heart failure was approved in part thanks to the VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical study run by researchers at the University of Alberta s Canadian VIGOUR Centre.
As reported in March 2020, vericiguat works by stimulating an enzyme in the body called soluble guanylate cyclase (sGC), which is important for enhancing heart function and helping blood vessels relax to provide better blood flow. In patients with heart failure, sGC is reduced and unable to adequately stimulate cyclic guanosine monophosphate (cGMP), necessary for transmitting chemical signals to blood vessels, which results in vascular and coronary dysfun